Core Insights - Regeneron Pharmaceuticals, Inc. has reported positive results from Phase 3 trials for treatments targeting cat and birch allergies, meeting primary and key secondary endpoints [1][4]. Cat-Allergen Treatment - The trial involved two monoclonal antibodies, REGN1908 and REGN1909, which target FelD1, a major cat allergen. Participants received either the antibody combination (n=33) or a placebo (n=31) [2]. - The primary endpoint of ocular itch was reduced by 52%, with key secondary endpoints showing a 39% reduction in conjunctival redness and a 44% reduction in skin prick reactivity. In a specific subgroup, ocular itch reduction reached 64% and conjunctival redness reduction was 49% [3]. - The combination therapy was well-tolerated, with no serious treatment-related adverse events reported, and the trial is ongoing for further safety follow-up [4]. Birch-Allergen Treatment - The birch allergy trial utilized REGN5713 and REGN5715, targeting BetV1, the primary allergenic protein in birch pollen. Participants were randomized to receive the antibody combination (n=27) or a placebo (n=27) [4][5]. - Results showed a 51% reduction in itch, a 46% reduction in conjunctival redness, and a 44% reduction in skin prick reactivity. The therapy was also well-tolerated with no serious adverse events [5]. Broader Allergy Pipeline - The cat and birch allergy programs are part of a larger allergy pipeline, which includes an ongoing proof-of-concept trial for severe food allergies, with enrollment expected to be completed by the end of the year [6]. - Regeneron plans to initiate additional Phase 3 development for the birch allergy treatment by the end of 2023 and for the cat allergy treatment in the first half of 2026 [4][5]. Market Reaction - Following the announcement, Regeneron Pharmaceuticals' stock experienced a decline of 3.05%, trading at $555.92 [6].
What's Happening With Regeneron Pharmaceuticals Stock On Monday?